SCHEMBL10241847

SCHEMBL10241847

CC(C)(C)OC(=O)NC(CNC(=N)NN=O)C(=O)ON1C(=O)CCC1=O

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 2/20 0.34
▸ KMT2A Q03164 1/20 0.34
▸ CTSS P25774 11/20 0.33
▸ CTSK P43235 9/20 0.33
▸ AKT1 P31749 1/20 0.32
▸ CTSL P07711 2/20 0.32
▸ CTSB P07858 2/20 0.32
▸ CYP1A2 P05177 1/20 0.32
▸ CYP2C9 P11712 1/20 0.32
▸ CYP2C19 P33261 1/20 0.32
▸ HTT P42858 1/20 0.32
▸ NFKB1 P19838 1/20 0.32
▸ NFKB2 Q00653 1/20 0.32
▸ RELA Q04206 1/20 0.32
▸ PPARG P37231 1/20 0.31
▸ PPARA Q07869 1/20 0.31
▸ SYK P43405 1/20 0.31
▸ CYP3A4 P08684 1/20 0.31
▸ SCN9A Q15858 1/20 0.31
▸ KDM4E B2RXH2 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18226807 0.86 CTSS (0.40) ALDH1A1KMT2ACTSSCTSKAKT1
SCHEMBL18226806 0.86 CTSS (0.40) ALDH1A1KMT2ACTSSCTSKAKT1
SCHEMBL10148209 0.85 PPARG (0.34) ALDH1A1CTSSCTSKAKT1CTSL
SCHEMBL3752128 0.79 CYP1A2 (0.38) ALDH1A1KMT2ACTSSCTSKAKT1
SCHEMBL22199794 0.79 CTSK (0.46) ALDH1A1KMT2ACTSSCTSKAKT1
SCHEMBL14984705 0.79 CYP1A2 (0.38) ALDH1A1KMT2ACTSSCTSKAKT1
SCHEMBL16108889 0.79 CTSK (0.46) ALDH1A1KMT2ACTSSCTSKAKT1
SCHEMBL10347068 0.79 CYP1A2 (0.38) ALDH1A1KMT2ACTSSCTSKAKT1
SCHEMBL356226 0.79 CTSK (0.46) ALDH1A1KMT2ACTSSCTSKAKT1
SCHEMBL30538844 0.78 HDAC4 (0.37) ALDH1A1KMT2ACTSSCTSKAKT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8101661-B2 Polar hydrophilic prodrugs and non-standard amino acid conjugates of amphetamine and other stimulants and processes for making and using the same KEMPHARM, INC. (US) 2012-01-24 — — US disclosed
US-20110213034-A1 Polar Hydrophilic Prodrugs of Amphetamine and Other Stimulants and Processes for Making and Using the Same SHIRE LLC 2011-09-01 — — US disclosed
US-20100292336-A1 Polar Hydrophilic Prodrugs and Non-Standard Amino Acid Conjugates of Amphetamine and Other Stimulants and Processes for Making and Using the Same TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-11-18 — — US disclosed
US-20100292337-A1 Polar Hydrophilic Prodrugs of Amphetamine and Other Stimulants and Processes for Making and Using the Same SHIRE LLC 2010-11-18 — — US disclosed
US-7772222-B2 Polar hydrophilic prodrugs of amphetamine and other stimulants and processes for making and using the same TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-08-10 — — US disclosed
US-20090239949-A1 Polar Hydrophilic Prodrugs of Amphetamine and Other Stimulants and Processes for Making and Using the Same SHIRE LLC 2009-09-24 — — US disclosed
US-20080207757-A1 Polar Hydrophilic Prodrugs of Amphetamine and Other Stimulants and Processes for Making and Using the Same TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-08-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100292337-A1 Polar Hydrophilic Prodrugs of Amphetamine and Other Stimulants and Processes for Making and Using the Same SLC6A2, SLC6A3, SLC18A2 ALDH1A1 1191/4885KMT2A 1364/4885CTSS 2420/4885
US-20090239949-A1 Polar Hydrophilic Prodrugs of Amphetamine and Other Stimulants and Processes for Making and Using the Same SLC6A2, SLC6A3, SLC18A2 ALDH1A1 1191/4885KMT2A 1364/4885CTSS 2420/4885
US-20100292336-A1 Polar Hydrophilic Prodrugs and Non-Standard Amino Acid Conjugates of Amphetamine and Other Stimulants and Processes for Making and Using the Same SLC18A2, SLC6A19, SLC6A2 ALDH1A1 1308/4885KMT2A 906/4885CTSS 2715/4885
US-20110213034-A1 Polar Hydrophilic Prodrugs of Amphetamine and Other Stimulants and Processes for Making and Using the Same SLC6A3, SLC6A2, SLC6A15 ALDH1A1 1748/4885KMT2A 985/4885CTSS 2888/4885
US-20080207757-A1 Polar Hydrophilic Prodrugs of Amphetamine and Other Stimulants and Processes for Making and Using the Same SLC6A2, SLC6A3, SLC18A2 ALDH1A1 1191/4885KMT2A 1364/4885CTSS 2420/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback